Abstract
Purpose
Central nervous system (CNS) dissemination occurs in 4.1% of mantle cell lymphoma (MCL) patients and clinically significant CNS involvement in chronic lymphocytic leukemia (CLL) patients reaches 4%. Ibrutinib, an orally administered Bruton’s tyrosine kinase (BTK) inhibitor, has shown substantial activity in CLL or MCL patients with CNS localization, and in primary central nervous system lymphoma (PCNSL). The drug efficacy to treat primary or secondary CNS impairments relies on its brain distribution through the blood–brain barrier (BBB), the aim of the present work was to study the brain distribution of ibrutinib using an in vivo mice model.
Methods
Brain and plasma pharmacokinetics of ibrutinib were assessed in a healthy Swiss mice model. Brain accumulation of ibrutinib was evaluated through an escalation single-dose study and a multiple-dose study in whole brain and in its specific anatomic structures. Ibrutinib plasma and brain quantification was performed using a validated liquid-chromatography mass tandem spectrometry method.
Results
Maximal concentration of ibrutinib in plasma and brain were close thus showing that ibrutinib rapidly crosses the BBB in 0.29 h (0.2–0.32 h) [median (min–max)]. Ibrutinib brain exposure was also correlated to the dose, and correlated to plasma exposure. AUC0−t brain to AUC0−t plasma ratio average for ibrutinib was found to reach 0.7 and ibrutinib accumulates in the ventricle area.
Conclusion
The high level of ibrutinib brain distribution supports the clinical efficacy of this drug in CNS localization of MCL, CLL or PCNSL.
Abbreviations
- AUC:
-
Area under the curve
- MCL:
-
Mantle cell lymphoma
- CNS:
-
Central nervous system
- PCNSL:
-
Central nervous system lymphoma
- IBR:
-
Ibrutinib
References
Brown JR, Hillmen P, O/‘Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC (2018) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia 32(1):83–91
Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S (2015) Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 126(6):739–745
Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF (2013) Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network†. Ann Oncol 24(8):2119–2123
Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, Chaffee KG, Call TG, Shanafelt TD (2016) Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica 101(4):458–465
Cramer SC, Glaspy JA, Efird JT, Louis DN (1996) Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Neurology 46(1):19–25
Grommes C, Pastore A, Gavrilovic I, Kaley T, Nolan C, Omuro AM, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L (2016) Single-agent Ibrutinib in recurrent/refractory central nervous system lymphoma. Blood 128(22):783–783
Bernard S, Goldwirt L, Amorim S, Brice P, Briere J, Sauvageon H, Thieblemont C (2014) Promising results of Ibrutinib in three patients with secondary central nervous system mantle cell lymphoma In. American Society of Heamatology, San Francisco
Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH (2017) Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma. Cancer Cell 31(6):833–843.e835
Jetté L, Murphy GF, Leclerc J-M, BÈliveau R (1995) Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 50(10):1701–1709
Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97(11):2517–2524
Hoppe SV, Rood G-J, Wagenaar E, Sparidans R, Beijnen J, Schinkel A (2017) Abstract 5218: breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) transport ibrutinib and may restrict its oral availability and brain accumulation, whereas CYP3A4 limits ibrutinib oral availability. Can Res 77(13 Supplement):5218–5218
Zhang H, Patel A, Ma S-L, Li XJ, Zhang Y-K, Yang P-Q, Kathawala RJ, Wang Y-J, Anreddy N, Fu L-W, Chen Z-S (2014) In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1. Br J Pharmacol 171(24):5845–5857
FDA (2013) Clinical pharmacology and pharmacology reviews Ibrutinib—Application number 205552Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000ClinPharmR.pdf. Accessed 22 Feb 2018
Mannina D, Loteta B (2017) Ibrutinib treatment of mantle cell lymphoma relapsing at central nervous system: a case report and literature review. Case Rep Hematol 2017:1–4, Article ID 9583257
Huynh HH, Pressiat C, Sauvageon H, Madelaine I, Maslanka P, Lebbe C, Thieblemont C, Goldwirt L, Mourah S (2017) Development and validation of a simultaneous quantification method of 14 tyrosine kinase inhibitors in human plasma using LC-MS/MS. Ther Drug Monit 39(1):43–54
Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharm Biopharm 16(3):303–309
Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R (2015) Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood 125(13):2079–2086
Shakeel F, Salem-Bekhit MM, Iqbal M, Haq N (2015) Solubility and thermodynamic function of a new anticancer drug ibrutinib in 2-(2-ethoxyethoxy)ethanol + water mixtures at different temperatures. J Chem Thermodyn 89:159–163
Gad SC, Cassidy CD, Aubert N, Spainhour B, Robbe H (2006) Nonclinical vehicle use in studies by multiple routes in multiple species. Int J Toxicol 25(6):499–521
Pouzoulet F, Rezai K, Li Z, Yushi Q, Tun HW, Labiod D, Bonnet-Boissinot S, Soussain C (2016) Preclinical evaluation of Ibrutinib for central nervous system lymphoma. Blood 128(22):4170–4170
Akinleye A, Chen Y, Mukhi N, Song Y, Liu D (2013) Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 6:59–59
Peñalver F-J, Sancho J-M, de la Fuente A, Olave M-T, Martín A, Panizo C, Pérez E, Salar A, Orfao A (2017) Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica 102(2):235–245
Go JL, Sandy C, Lee a PE, Kim (2006) Imaging of primary central nervous system lymphoma. Neurosurg Focus 21(5):1–6
Bonnet C, Lamy T, Fruchart C, Le Gouill S, Gunzer K, Gastinne T, Jardin F, Karlin L, Houot R, Dupuis J, Tilly H, Salles GA (2016) Ibrutinib in association with R-DHAP/Ox for patients with relapsed/refractory B-cell lymphoma: preliminary results of the Biblos Phase Ib Lysa Study. Blood 128(22):5384–5384
Martin P, Blum K, Bartlett NL, Park SI, Maddocks KJ, Ruan J, Di Liberto M, Huang X, Inghirami G, Harris P, Chen-Kiang S, Leonard JP (2016) A phase I trial of Ibrutinib Plus Palbociclib in patients with previously treated mantle cell lymphoma. Blood 128(22):150–150
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest to declare.
Ethical statement
All procedures involving animals were conducted in strict adherence to the French law for animal care and handling. (Authorization no. 2015071616316531.01).
Rights and permissions
About this article
Cite this article
Goldwirt, L., Beccaria, K., Ple, A. et al. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol 81, 783–789 (2018). https://doi.org/10.1007/s00280-018-3546-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-018-3546-3